Literature DB >> 21986262

The changing pathology of lung cancer.

Zhen Fan1, Richard Schraeder.   

Abstract

Lung cancer classification is of paramount importance in determining the treatment for oncologic patients. Most lung cancers are non-small cell lung carcinomas (NSCLC), which are further subclassified into squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Lung neuroendocrine tumors are subclassified into typical carcinoid, atypical carcinoid, small cell carcinoma, and large cell neuroendocrine carcinoma. In NSCLC in particular, the histologic classification and tumor mutation analysis are central to today's targeted therapy and personalized treatment. This article discusses the current diagnostic criteria for classification of NSCLC and lung neuroendocrine tumors and implications for oncologic treatment. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21986262     DOI: 10.1016/j.soc.2011.07.004

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  7 in total

Review 1.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 2.  Treatment of limited disease small cell lung cancer: the multidisciplinary team.

Authors:  Markus Glatzer; Achim Rittmeyer; Joachim Müller; Isabelle Opitz; Alexandros Papachristofilou; Ioannis Psallidas; Martin Früh; Diana Born; Paul Martin Putora
Journal:  Eur Respir J       Date:  2017-08-24       Impact factor: 16.671

3.  Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis.

Authors:  Xue-Jiao Lv; Li-Jing Zhao; Yu-Qiu Hao; Zhen-Zhong Su; Jun-Yao Li; Yan-Wei Du; Jie Zhang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  Associations between history of chronic lung disease and non-small cell lung carcinoma in Maryland: variations by sex and race.

Authors:  Lisa D Gardner; Christopher A Loffredo PhD; Patricia Langenberg; Diane Marie St George; Janaki Deepak; Curtis C Harris; Sania Amr
Journal:  Ann Epidemiol       Date:  2018-05-07       Impact factor: 3.797

5.  Clinicopathological and prognostic significance of metastasis-associated protein 1 expression and its correlation with angiogenesis in lung invasive adenocarcinomas, based on the 2011 IASLC/ATS/ERS classification.

Authors:  Shuhai Li; Hui Tian; Weiming Yue; Lin Li; Cun Gao; Libo Si; Wensi Hu; Lei Qi; Ming Lu; Chuanle Cheng; Jingjing Cui; Guanqing Chen
Journal:  Oncol Lett       Date:  2015-10-29       Impact factor: 2.967

6.  Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients.

Authors:  You-Yi Chen; Shih-Chieh Chang; Cheng-Yu Chang; Chun-Fu Chang; Yi-Chun Lai; Yu-Feng Wei; Chung-Yu Chen
Journal:  BMC Cancer       Date:  2021-11-15       Impact factor: 4.430

7.  Ku80 is highly expressed in lung adenocarcinoma and promotes cisplatin resistance.

Authors:  Qingshan Ma; Ping Li; Minyu Xu; Jinzhi Yin; Zhenzhong Su; Wei Li; Jie Zhang
Journal:  J Exp Clin Cancer Res       Date:  2012-11-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.